



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai

IOLCP/CGC/2017
13 November 2017

Subject: Disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 13 November 2017 had approved the following:

1. Un-audited Financial Results of the Company for the quarter and half year ended 30 September 2017.
2. To enhance the manufacturing capacity of Ibuprofen from 7200 TPA to 12000 TPA and enhance the capacities of backward integrated products i.e. Iso butyl Benzene from 9000 TPA to 12000 TPA, MCA from 7200 TPA to 10500 TPA and Acetyl Chloride from 5200 TPA to 8400 TPA with a project cost of ₹ 200 crore which will be met through combination of equity, internal accruals and loans over a period of two years.
3. Setting up Unit IV for manufacturing Metformin an anti diabetic drug with a capacity of 2880 MT per annum with project cost of ₹ 10 crore which will be financed through internal accruals.

Further the Company has completed and commercialized Unit III to manufacture Fenofibrate, Clopidogrel and Lamotrigine etc. with project cost of ₹ 16.48 crore met through internal accruals.

Please find enclosed herewith the following:


1. Un-audited Financial Results for the quarter and half year ended 30 September 2017
2. Independent Auditors' Review Report on the Un-audited Financial Results for the quarter and half year ended 30 September 2017.

Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 04:50 p.m.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

[Krishan Singla]
Vice President & Company Secretary



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292




IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2017

(Rs. in Crore)

Sr. No.	Particulars	Quarter ended			Half year ended	
		(Unaudited) 30.09.2017	(Unaudited) 30.06.2017	(Unaudited) 30.09.2016	(Unaudited) 30.09.2017	(Unaudited) 30.09.2016
I	Revenue from operations (refer note no.2)	217.79	232.97	187.46	450.76	367.98
II	Other Income	0.35	0.33	0.32	0.68	0.63
III	Total revenue (I+II)	218.14	233.30	187.78	451.44	368.61
IV	Expenses					
	Cost of materials consumed	136.37	148.50	132.61	284.87	240.13
	Purchase of stock-in-trade	0.40	-	-	0.40	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	12.81	2.83	(17.84)	15.64	(18.62)
	Employee benefits expense	13.99	13.55	10.95	27.54	21.91
	Finance costs	16.61	17.14	16.77	33.75	34.01
	Depreciation and amortization expense	7.57	7.31	7.47	14.88	14.94
	Excise duty on sales (refer note no.2)	-	17.66	15.11	17.66	33.65
	Other expenses	24.55	23.14	21.45	47.69	40.31
	Total Expenses	212.30	230.13	186.52	442.43	366.33
V	Profit/(loss) before exceptional items and tax (III-IV)	5.84	3.17	1.26	9.01	2.28
VI	Exceptional items	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	5.84	3.17	1.26	9.01	2.28
VIII	Tax Expense					
	(i) Current tax	1.38	0.64	0.27	2.02	0.48
	(ii) Deferred tax	0.03	(0.45)	0.04	(0.42)	0.14
	Total tax expense	1.41	0.19	0.31	1.60	0.62
IX	Profit/(loss) for the period for continuing operation (VII-VIII)	4.43	2.98	0.95	7.41	1.66
X	Profit/(loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	4.43	2.98	0.95	7.41	1.66
XIV	Other Comprehensive Income					
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising profit/(loss) and other comprehensive income for the period)	4.43	2.98	0.95	7.41	1.66
XVI	Paid-up equity share capital (Face value Rs.10/- per share)	56.21	56.21	56.21	56.21	56.21
XVII	Earning per equity share of Rs.10/- each (for continuing operations)					
	Basic	0.79	0.53	0.17	1.32	0.30
	Diluted	0.79	0.53	0.17	1.32	0.30
	Cash	2.14	1.75	1.51	3.89	2.98
XVIII	Earning per equity share of Rs.10/- each (for discontinued operations)					
	Basic	-	-	-	-	-
	Diluted	-	-	-	-	-
	Cash	-	-	-	-	-
XIX	Earning per equity share of Rs.10/- each (for continuing and discontinued operations)					
	Basic	0.79	0.53	0.17	1.32	0.30
	Diluted	0.79	0.53	0.17	1.32	0.30
	Cash	2.14	1.75	1.51	3.89	2.98



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Ph.) India CIN - L24116PB1986PLC007036
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Ph.) India
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Balance Sheet as at 30 September 2017

Rs. in Crore

Particulars	As at 30.09.2017
ASSETS	
1 Non-current assets	
(a) Property, Plant and Equipment	384.40
(b) Capital work in progress	18.01
(c) Intangible assets	0.80
(d) Financial assets	
(i) Investments	0.03
(ii) Other Non current assets	12.17
Total non-current assets	415.41
2 Current Assets	
(a) Inventories	240.53
(b) Financial assets	
(i) investments	0.06
(ii) Trade receivables	126.98
(iii) Cash and cash equivalents	12.04
(iv) Bank Balances [other than (iii) above]	17.12
(v) Other financial assets	0.52
(c) Other current assets	20.54
Total current assets	417.79
TOTAL ASSETS	833.20
EQUITY AND LIABILITIES	
Equity	
(a) Share capital	56.21
(b) Other equity	139.71
Total equity	195.92
Liabilities	
1 Non-current liabilities	
(a) Financial Liabilities	
Borrowings	270.26
(b) Provisions	2.53
(c) Deferred tax liabilities	1.61
(d) Other long term liabilities	1.93
Total non-current liabilities	276.33
2 Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	166.24
(ii) Trade payables	151.46
(iii) Other financial liabilities	41.50
(b) Other current liabilities	1.25
(c) Provisions	0.03
(d) Current tax liabilities (net)	0.47
Total current liabilities	360.95
TOTAL EQUITY AND LIABILITIES	833.20



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Ph.) India CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Ph.) India

Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.

Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, along with the quarterly results

(Rs. in Crore)

Sr.No.	Particulars	Quarter ended			Half year ended	
		(Unaudited) 30.09.2017	(Unaudited) 30.06.2017	(Unaudited) 30.09.2016	(Unaudited) 30.09.2017	(Unaudited) 30.09.2016
1	Segment Revenue					
	(Net sale/income)					
	- Chemicals	104.94	113.59	97.52	218.53	196.98
	- Drugs	143.78	130.28	99.37	274.06	184.24
	- Unallocated	2.55	0.62	0.66	3.17	1.44
	Total	251.27	244.49	197.55	495.76	382.66
	Less : Inter segment revenue	33.13	28.85	24.88	61.98	47.70
	Net sales/income from operations	218.14	215.64	172.67	433.78	334.96
2	Segment Results					
	Profit(+)/(loss)(-) before tax and interest from each segment)					
	- Chemicals	0.86	0.40	(1.41)	1.26	(3.17)
	- Drugs	21.46	18.85	18.85	40.31	38.81
	Total	22.32	19.25	17.44	41.57	35.64
	Less: Interest	16.61	17.14	16.77	33.75	34.01
	Add: Other un-allocable income net off un-allocable expenditure	0.13	1.06	0.59	1.19	0.65
	Income Tax (Net)					
	Total Profit(+)/(loss) (-) before tax & Extraordinary items	5.84	3.17	1.26	9.01	2.28
3	Segment Assets					
	- Chemicals	298.83	303.60	316.38	298.83	316.38
	- Drugs	485.93	488.43	441.68	485.93	441.68
	- Unallocated	48.45	40.39	32.92	48.45	32.92
	Total Assets	833.21	832.42	790.98	833.21	790.98
4	Segment Liabilities					
	- Chemicals	282.82	293.96	298.64	282.82	298.64
	- Drugs	332.42	329.28	295.39	332.42	295.39
	- Unallocated	22.05	17.70	10.93	22.05	10.93
	Total Liabilities	637.29	640.94	604.96	637.29	604.96

Notes:

- The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 13 November 2017. These results have been subjected to limited review by the Statutory Auditors.
- Post implementation of Goods and Service Tax (GST) w.e.f. 01 July 2017, revenue from operations is disclosed net of GST. Accordingly, revenue from operations for the quarter and half year ended 30 September 2017 are not comparable with those of the previous periods presented in the results.

Had the previously reported revenue shown net of excise duty, comparative revenue of the company would have been as follows:

(Rs. in Crore)

Particulars	Quarter ended			Half year ended	
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016
Net revenue from operations	217.79	215.31	172.35	433.10	334.33

- The Company has successfully set up unit III to manufacture existing pipe line APIs i.e. Fenofibrate, Clopidogrel, Lamotrigine etc. with project cost of Rs.16.48 crore which was financed through internal accruals.
- The Company is in process to setting up Unit IV for manufacturing Metformin an anti diabetic drug with a capacity of 2880 TPA with project cost of Rs.10 crore which will be financed through internal accruals.
- The company has planned to enhance the existing manufacturing capacities which will result in increase in capacities of Ibuprofen from 7200 TPA to 12000 TPA and also enhance the capacities of backward integrated products i.e. Iso butyl Benzene from 9000 TPA to 12000 TPA, Mono Chloro Acetic Acid from 7200 TPA to 10500 TPA and Acetyl Chloride from 5200 TPA to 8400 TPA with a project cost of Rs.200 crore which will be met through combination of equity, internal accruals and loans over a period of two years.


Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.

Ph. : +91-1679 -285285-86, Fax : +91-1679-285292






IOL CHEMICALS AND PHARMACEUTICALS LIMITED

6. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (being transition from 01 April 2016).
7. The Ind AS financial results for the quarter ended 30 September 2016 have not been subjected to any limited review.
8. The reconciliation of the financial results for the quarter and half year ended 30 September 2016 to those reported under previous Generally Accepted Accounting Principles (GAAP) is summarised as follows:

Particulars	(Rs. in Crore)	
	Quarter ended 30.09.2016	Half year ended 30.09.2016
Profits after tax as per previous Indian GAAP	0.98	1.71
Add/less adjustments		
Loan processing fees recognised using effective interest method	(0.06)	(0.12)
Profit on reinstatement of investments	-	0.01
Subsidy income amortized	0.03	0.06
Reversal of depreciation on account of loan processing fee decapitalised	0.02	0.04
Additional depreciation on account of capital subsidy capitalised	(0.02)	(0.04)
Deferred tax adjustments	-	-
Total adjustments	(0.03)	(0.05)
Ind AS	0.95	1.66

9. Figures for the previous corresponding period have been regrouped, wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited



Vijay Garg
Vijay Garg
Managing Director
CIN: 06510248

Place: Ludhiana
Date: 13 November 2017

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

INDEPENDENT AUDITOR'S REVIEW REPORT

To
The Board of Directors,
IOL Chemicals and Pharmaceuticals Limited,
Ludhiana.

Introduction

We have reviewed the accompanying statement of unaudited financial results of IOL Chemicals and Pharmaceuticals Limited (the Company) for the quarter and six months period ended 30th September, 2017 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations").

This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Matters

We draw attention to the following matters:

- a. Refer Note 6 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017 and accordingly, the Statement has been prepared in compliance with Ind AS.
- b. We have not reviewed the comparative figures including the reconciliation of Total Comprehensive Income for the quarter and six months period ended on 30th September, 2016 and accordingly, we do not express any conclusion on the results in the Statement for the quarter and six months period ended 30th September, 2016. These figures have been furnished to us by the Management.

Our conclusion is not qualified in respect of these matters.

Dated: 13th November, 2017
Place: Ludhiana



For S.C. Vasudeva & Co.
Chartered Accountants
Registration No.00235N


(Sanjiv Mohan)
Partner
M. No. 086066